A-FIB
MCID: ATR011
MIFTS: 66

Atrial Fibrillation (A-FIB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Mental diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Atrial Fibrillation

MalaCards integrated aliases for Atrial Fibrillation:

Name: Atrial Fibrillation 12 36 29 54 6 42 3 44 15 62 62 17 70
Fibrillation, Atrial 39
a-Fib 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060224
KEGG 36 H00731
ICD9CM 34 427.31
MeSH 44 D001281
NCIt 50 C50466
SNOMED-CT 67 266306001
UMLS 70 C0004238

Summaries for Atrial Fibrillation

PubMed Health : 62 About atrial fibrillation: Atrial fibrillation (A-tre-al fi-bri-LA-shun), or AF, is the most common type of arrhythmia (ah-RITH-me-ah). An arrhythmia is a problem with the rate or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. AF occurs if rapid, disorganized electrical signals cause the heart's two upper chambers—called the atria (AY-tree-uh)—to fibrillate. The term "fibrillate" means to contract very fast and irregularly. In AF, blood pools in the atria. It isn't pumped completely into the heart's two lower chambers, called the ventricles (VEN-trih-kuls). As a result, the heart's upper and lower chambers don't work together as they should. People who have AF may not feel symptoms. However, even when AF isn't noticed, it can increase the risk of stroke. In some people, AF can cause chest pain or heart failure, especially if the heart rhythm is very rapid. AF may happen rarely or every now and then, or it may become an ongoing or long-term heart problem that lasts for years.

MalaCards based summary : Atrial Fibrillation, also known as fibrillation, atrial, is related to congestive heart failure and long qt syndrome 10, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Atrial Fibrillation is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Vascular smooth muscle contraction and Adrenergic signaling in cardiomyocytes. The drugs Ranolazine and Isoproterenol have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and brain, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

MedlinePlus : 42 An arrhythmia is a problem with the speed or rhythm of the heartbeat. Atrial fibrillation (AF) is the most common type of arrhythmia. The cause is a disorder in the heart's electrical system. Often, people who have AF may not even feel symptoms. But you may feel Palpitations -- an abnormal rapid heartbeat Shortness of breath Weakness or difficulty exercising Chest pain Dizziness or fainting Fatigue Confusion AF can lead to an increased risk of stroke. In many patients, it can also cause chest pain, heart attack, or heart failure. Doctors diagnose AF using family and medical history, a physical exam, and a test called an electrocardiogram (EKG), which looks at the electrical waves your heart makes. Treatments include medicines and procedures to restore normal rhythm. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Atrial fibrillation, often called AFib or AF, is the most common type of heart arrhythmia. An arrhythmia is when the heart beats too slowly, too fast, or in an irregular way. When a person has AFib, the normal beating in the upper chambers of the heart (the two atria) is irregular, and blood doesn't flow as well as it should from the atria to the lower chambers of the heart (the two ventricles). AFib may occur in brief episodes, or it may be a permanent condition.

KEGG : 36 Atrial fibrillation (AF, ATFB) is the most common cardiac arrhythmia and is regarded generally as a sporadic, acquired disorder. Nevertheless, recent growing evidence points to an important heritable basis for AF. By linkage analysis, several loci have been mapped for monogenetic AF. Some of these loci encode for subunits of potassium channels.

Wikipedia : 73 Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm (arrhythmia) characterized by the rapid... more...

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 929)
# Related Disease Score Top Affiliating Genes
1 congestive heart failure 32.7 SCN5A NPPB NPPA KCNQ1
2 long qt syndrome 10 32.5 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
3 cardiac arrhythmia 32.3 SCN5A SCN3B SCN1B KCNQ1 KCNH2 KCNE2
4 familial sick sinus syndrome 32.2 SCN5A HCN4
5 short qt syndrome 32.2 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2
6 atrial standstill 1 32.1 SCN5A SCN1B NPPB GJA5 ABCC9
7 wolff-parkinson-white syndrome 32.1 SCN5A NPPB KCNQ1 ABCC9
8 familial atrial fibrillation 32.0 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
9 syncope 32.0 SCN5A NPPA KCNQ1 KCNH2
10 ventricular fibrillation, paroxysmal familial, 1 32.0 SCN5A KCNQ1 KCNH2 KCNE2
11 cardiac conduction defect 31.9 SCN5A SCN1B KCNQ1
12 sick sinus syndrome 31.9 SNTA1 SCN5A SCN3B SCN1B NPPA HCN4
13 myocardial infarction 31.9 SCN5A NPPB NPPA MYL4 KCNQ1 ABCC9
14 atrioventricular block 31.9 SCN5A NPPB KCNQ1 KCNH2 KCNE2 HCN4
15 heart disease 31.8 ZFHX3 SCN5A NPPB NPPA MYL4 KCNQ1
16 progressive familial heart block, type ia 31.8 SCN5A GJA5 ANK2
17 atrial heart septal defect 31.8 SCN5A NPPB NPPA HCN4 GJA5
18 cardiac arrhythmia, ankyrin-b-related 31.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2
19 patent foramen ovale 31.5 NPPB NPPA GJA5
20 lipoprotein quantitative trait locus 31.5 ZFHX3 SCN5A NPPB NPPA KCNQ1 KCNJ2
21 hypertrophic cardiomyopathy 31.5 SCN5A NPPB NPPA KCNQ1 KCNJ2 KCNH2
22 sinoatrial node disease 31.4 SCN5A SCN3B SCN1B KCNQ1 KCNJ2 KCNH2
23 left bundle branch hemiblock 31.4 SCN5A NPPB
24 cardiac arrest 31.4 SCN5A NPPB KCNQ1 KCNH2 HCN4 ANK2
25 aortic valve disease 2 31.2 NPPB NPPA MYL4
26 right bundle branch block 31.1 SCN5A SCN3B SCN2B SCN1B NPPB KCNH2
27 atrial standstill 31.0 SCN5A NPPA GJA5
28 first-degree atrioventricular block 31.0 SCN5A NPPB KCNJ2 KCNH2
29 second-degree atrioventricular block 31.0 SCN5A SCN3B HCN4
30 brugada syndrome 1 30.9 SCN5A KCNH2 KCNA5
31 third-degree atrioventricular block 30.8 SCN5A SCN1B NPPB KCNJ2 KCNH2 HCN4
32 tetralogy of fallot 30.8 SCN5A NPPB NPPA KCNH2 GJA5
33 familial short qt syndrome 30.8 KCNQ1 KCNJ2 KCNH2
34 dilated cardiomyopathy 30.7 SNTA1 SCN5A SCN4B SCN2B NPPB NPPA
35 arrhythmogenic right ventricular cardiomyopathy 30.7 SCN5A NPPB KCNH2 HCN4 ANK2 ABCC9
36 anterolateral myocardial infarction 30.4 NPPB NPPA
37 long qt syndrome 30.4 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
38 progressive familial heart block 30.4 SCN5A SCN1B KCNQ1 KCNH2 HCN4 GJA5
39 ebstein anomaly 30.4 SCN5A HCN4 GJA5
40 familial long qt syndrome 30.3 SNTA1 SCN5A SCN4B KCNQ1 KCNH2 KCNE2
41 brugada syndrome 30.3 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
42 left ventricular noncompaction 30.2 SNTA1 SCN5A SCN3B SCN2B SCN1B KCNQ1
43 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 30.1 SCN5A KCNQ1 KCNJ2 KCNH2 ANK2
44 brugada syndrome 5 30.1 SCN5A SCN1B
45 long qt syndrome 3 29.9 SNTA1 SCN5A SCN4B SCN3B SCN1B KCNQ1
46 catecholaminergic polymorphic ventricular tachycardia 29.9 SNTA1 SCN5A SCN4B SCN3B SCN1B KCNQ1
47 long qt syndrome 1 29.8 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
48 sudden infant death syndrome 29.7 SNTA1 SCN5A SCN4B SCN3B SCN2B SCN1B
49 long qt syndrome 5 29.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2
50 long qt syndrome 6 29.6 SNTA1 SCN5A SCN4B KCNQ1 KCNJ2 KCNH2

Graphical network of the top 20 diseases related to Atrial Fibrillation:



Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:


angina pectoris; chest pain; edema

GenomeRNAi Phenotypes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.55 MYL4
2 Decreased viability GR00249-S 9.55 ABCC9 GJA5 KCNE2 MYL4 NPPA SCN1B
3 Decreased viability GR00402-S-2 9.55 KCNE2 KCNJ2 KCNQ1 NPPA NUP155 SCN1B

MGI Mouse Phenotypes related to Atrial Fibrillation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 ABCC9 GJA5 HCN4 KCNA5 KCNH2 KCNJ2
2 homeostasis/metabolism MP:0005376 10 ABCC9 GJA5 KCNA5 KCNE2 KCNH2 KCNJ2
3 muscle MP:0005369 9.7 ABCC9 GJA5 HCN4 KCNA5 KCNH2 KCNJ2
4 nervous system MP:0003631 9.36 ABCC9 HCN4 KCNA5 KCNQ1 NUP155 SCN1B

Drugs & Therapeutics for Atrial Fibrillation

PubMed Health treatment related to Atrial Fibrillation: 62

Treatment for atrial fibrillation (AF) depends on how often you have symptoms, how severe they are, and whether you already have heart disease . General treatment options include medicines, medical procedures, and lifestyle changes.

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 385)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
2
Isoproterenol Approved, Investigational Phase 4 7683-59-2 3779
3
Hydroxychloroquine Approved Phase 4 118-42-3 3652
4
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
5
Canrenoic acid Approved, Withdrawn Phase 4 4138-96-9
6
carbamide peroxide Approved Phase 4 124-43-6
7
Quinidine Approved, Investigational Phase 4 56-54-2 441074
8
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
9
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
10
Terazosin Approved Phase 4 63590-64-7 5401
11
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
12
fluindione Approved, Investigational Phase 4 957-56-2
13
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
14
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
16
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
17
Antazoline Approved Phase 4 91-75-8 2200
18
Nifedipine Approved Phase 4 21829-25-4 4485
19
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
20
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
22
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
24
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
25
Ezetimibe Approved Phase 4 163222-33-1 150311
26
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
28
Pantoprazole Approved Phase 4 102625-70-7 4679
29
Propranolol Approved, Investigational Phase 4 525-66-6 4946
30
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
31
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
32
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
33
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
34
Bisoprolol Approved Phase 4 66722-44-9 2405
35
Amlodipine Approved Phase 4 88150-42-9 2162
36
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
37
Atorvastatin Approved Phase 4 134523-00-5 60823
38
Ticlopidine Approved Phase 4 55142-85-3 5472
39
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
40
Liraglutide Approved Phase 4 204656-20-2 44147092
41
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
42
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
43
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
44
Methohexital Approved Phase 4 151-83-7 9034
45
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
46
tannic acid Approved Phase 4 1401-55-4
47
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
48
Enoxaparin Approved Phase 4 9005-49-6 772
49
Verapamil Approved Phase 4 52-53-9 2520
50
Ticagrelor Approved Phase 4 274693-27-5 9871419

Interventional clinical trials:

(show top 50) (show all 2582)
# Name Status NCT ID Phase Drugs
1 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
2 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
3 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
4 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
5 A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation Unknown status NCT02389218 Phase 4 sequential drug adjustment (propafenone, sotalol or flecainide)
6 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
7 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
8 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
9 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
10 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
11 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
12 SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial Unknown status NCT02004509 Phase 4 anticoagulant by physician criteria
13 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
14 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
15 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Unknown status NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
16 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
17 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
18 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
19 Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion Following Catheter Ablation of Atrial Fibrillation Unknown status NCT02260206 Phase 4 Colchicine
20 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
21 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
22 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
23 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
24 Clinical Efficacy of Potassium Canrenoate - Canrenone in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation and Elevated Blood Pressure - a Pilot Randomized Controlled Trial. Unknown status NCT03536806 Phase 4 Saline 0.9%;Canrenone
25 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
26 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
27 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
28 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
29 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
30 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
31 A Randomized Study Comparing Dabigatran Etexilate Versus Warfarin in Chinese Patients With Nonvalvular Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention With Stenting (DES) Unknown status NCT03536611 Phase 4 dabigatran;warfarin
32 A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Unknown status NCT03088072 Phase 4 Edoxaban;Aspirin and Clopidogrel;Aspirin and Warfarin
33 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
34 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
35 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
36 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
37 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
38 Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation Unknown status NCT02673463 Phase 4 Spironolactone;Placebo
39 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
40 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
41 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
42 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
43 Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation:a Single-center Randomized Controlled Trial Unknown status NCT04209959 Phase 4 nifekalant
44 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
45 A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor Unknown status NCT02639793 Phase 4
46 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Unknown status NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
47 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
48 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
49 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
50 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 70 / NDF-RT 51 :


anisindione
Atenolol
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide
Disopyramide Phosphate
DITIAZ
dofetilide
ibutilide
ibutilide fumarate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Procainamide
Procainamide Hydrochloride
Propafenone
Propafenone Hydrochloride
Quinidine
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol
Sotalol Hydrochloride
Verapamil
Verapamil hydrochloride
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Atrial Fibrillation 29

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

40
Heart, Kidney, Brain, Endothelial, Thyroid, Atrioventricular Node, Neutrophil

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 30634)
# Title Authors PMID Year
1
Effects of corticosteroids on new-onset atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials. 42 61
33725992 2021
2
The frequency of gastroesophageal reflux when radiofrequency catheter ablation procedures for atrial fibrillation under general anesthesia with a supraglottic device: Observational pilot study. 42 61
33578560 2021
3
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. 42
33726018 2021
4
Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation. 54 61
20483000 2010
5
Association of ADRB1 gene polymorphism with atrial fibrillation. 54 61
20384459 2010
6
Predictive value of B-type natriuretic peptide for postoperative atrial fibrillation following pulmonary resection for lung cancer. 61 54
19896864 2010
7
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 54 61
20211293 2010
8
Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. 54 61
20170814 2010
9
[Associations of the genetic polymorphisms in CYP11B2 gene with nonfamilial structural atrial fibrillation]. 54 61
20193392 2009
10
Genetic polymorphism of KCNH2 confers predisposition of acquired atrial fibrillation in Chinese. 61 54
19490382 2009
11
Utility of brain natriuretic peptide as a predictor of atrial fibrillation after cardiac operations. 54 61
19699901 2009
12
Interactions of MinK and e-NOS gene polymorphisms appear to be inconsistent predictors of atrial fibrillation propensity, but long alleles of ESR1 promoter TA repeat may be a promising marker. 61 54
19860128 2009
13
The use of B-type natriuretic peptide in the management of patients with atrial fibrillation and dyspnea. 61 54
18619686 2009
14
Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation. 61 54
19632626 2009
15
Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. 54 61
19464473 2009
16
Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. 54 61
19265792 2009
17
Study of the factors related to atrial fibrillation after coronary artery bypass grafting: a search for a marker to predict the occurrence of atrial fibrillation before surgical intervention. 54 61
19327514 2009
18
Effects of exercise testing on natriuretic peptide secretion in patients with atrial fibrillation. 54 61
19378231 2009
19
Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease. 54 61
19117407 2009
20
Brain natriuretic peptide correlates with the extent of atrial fibrillation-associated silent brain lesions. 54 61
18823968 2008
21
Letter by Hong et al regarding article, "Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation". 54 61
18852373 2008
22
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 61 54
18929244 2008
23
Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. 61 54
18794401 2008
24
Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients. 54 61
18792876 2008
25
Mechanisms by which atrial fibrillation-associated mutations in the S1 domain of KCNQ1 slow deactivation of IKs channels. 54 61
18599533 2008
26
Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. 61 54
18638595 2008
27
Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. 61 54
18598963 2008
28
[Influence of electrical cardioversion on troponine I and brain natriuretic peptide (NT-proBNP) levels in patients with persistent atrial fibrillation/flutter]. 54 61
18979903 2008
29
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. 61 54
18614783 2008
30
[Clinical characteristics of patients with persistent atrial fibrillation referred for cardioversion: Spanish Cardioversion Registry (REVERSE)]. 61 54
18570785 2008
31
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. 54 61
18496132 2008
32
ACE inhibitors as antifibrotic agents in atrial fibrillation: potential relevance in cardiac surgery. 61 54
18495720 2008
33
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). 61 54
18222980 2008
34
[The therapeutic efficiency of complex-ACE inhibitor (perindopril) and traditional antiarrhythmic-treatment for prevention atrial fibrillation paroxysms after successful electric cardio version]. 54 61
18401049 2008
35
Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery. 61 54
18198239 2008
36
Brain natriuretic peptide as a surrogate marker for cardioembolic stroke with paroxysmal atrial fibrillation. 54 61
18799875 2008
37
Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation. 61 54
18666803 2008
38
N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. 54 61
18345329 2008
39
Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. 54 61
17875969 2007
40
[Can measurement of CRP and BNP concentrations be helpful in predicting relapses and therapy of atrial fibrillation?]. 61 54
18350718 2007
41
Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. 61 54
15851259 2005
42
Association of the human minK gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation. 54 61
12228786 2002
43
Hypofibrinolysis in atrial fibrillation. 54 61
9842006 1998
44
Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation: role of duration of atrial fibrillation. 54 61
9489971 1998
45
Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. 61 54
9183333 1997
46
Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. 54 61
1406859 1992
47
Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators. 61 54
2183405 1990
48
Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. 61
32700579 2021
49
Inadequate oral anticoagulation with warfarin in women with cerebrovascular event and history of atrial fibrillation: the FibStroke study. 61
33475002 2021
50
Catheter ablation superiority over the pharmacological treatments in atrial fibrillation: a dedicated review. 61
33783271 2021

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6 (show all 44)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SNTA1 NM_003098.2(SNTA1):c.1169C>T (p.Ala390Val) SNV Likely pathogenic 8476 rs121434500 GRCh37: 20:31998009-31998009
GRCh38: 20:33410203-33410203
2 SCN5A NM_198056.2(SCN5A):c.4478A>G (p.Lys1493Arg) SNV Likely pathogenic 67898 rs199473260 GRCh37: 3:38597211-38597211
GRCh38: 3:38555720-38555720
3 NUP155 NM_153485.3(NUP155):c.1348A>G (p.Met450Val) SNV Uncertain significance 977374 GRCh37: 5:37333735-37333735
GRCh38: 5:37333633-37333633
4 NEBL NM_006393.3(NEBL):c.1228-1338del Deletion Uncertain significance 977376 GRCh37: 10:21131116-21131116
GRCh38: 10:20842187-20842187
5 KCNJ2 NM_000891.2(KCNJ2):c.277G>A (p.Val93Ile) SNV Uncertain significance 30121 rs147750704 GRCh37: 17:68171457-68171457
GRCh38: 17:70175316-70175316
6 SCN5A NM_000335.4(SCN5A):c.1282G>A (p.Glu428Lys) SNV Uncertain significance 30048 rs199473111 GRCh37: 3:38647498-38647498
GRCh38: 3:38606007-38606007
7 HCN4 NM_005477.3(HCN4):c.2716G>A (p.Gly906Arg) SNV Uncertain significance 404123 rs373572497 GRCh37: 15:73615718-73615718
GRCh38: 15:73323377-73323377
8 SCN5A NM_000335.5(SCN5A):c.5958C>A (p.Asn1986Lys) SNV Uncertain significance 30045 rs199473335 GRCh37: 3:38591902-38591902
GRCh38: 3:38550411-38550411
9 MYH7 , MHRT NM_000257.4(MYH7):c.5190G>T (p.Met1730Ile) SNV Uncertain significance 617741 rs1566522989 GRCh37: 14:23884683-23884683
GRCh38: 14:23415474-23415474
10 TTN-AS1 , TTN NM_001267550.2(TTN):c.73391G>A (p.Arg24464Gln) SNV Uncertain significance 691684 rs750056949 GRCh37: 2:179437468-179437468
GRCh38: 2:178572741-178572741
11 TTN-AS1 , TTN NM_001267550.2(TTN):c.57399A>C (p.Leu19133Phe) SNV Uncertain significance 691692 rs1576219060 GRCh37: 2:179462410-179462410
GRCh38: 2:178597683-178597683
12 SCN5A NM_000335.4(SCN5A):c.414G>A (p.Met138Ile) SNV Uncertain significance 67865 rs199473060 GRCh37: 3:38663959-38663959
GRCh38: 3:38622468-38622468
13 TTN-AS1 , TTN NM_001267550.2(TTN):c.63976C>T (p.His21326Tyr) SNV Likely benign 691743 rs1413306492 GRCh37: 2:179451962-179451962
GRCh38: 2:178587235-178587235
14 TTN-AS1 , TTN NM_001267550.2(TTN):c.57356A>T (p.Lys19119Met) SNV Likely benign 691745 rs1576219870 GRCh37: 2:179462453-179462453
GRCh38: 2:178597726-178597726
15 TTN NM_001267550.2(TTN):c.44014G>A (p.Asp14672Asn) SNV Likely benign 691748 rs1339350914 GRCh37: 2:179495761-179495761
GRCh38: 2:178631034-178631034
16 TTN NM_001267550.2(TTN):c.42513T>A (p.His14171Gln) SNV Likely benign 691749 rs142842339 GRCh37: 2:179498713-179498713
GRCh38: 2:178633986-178633986
17 SCN5A NM_000335.5(SCN5A):c.5848G>T (p.Val1950Leu) SNV Likely benign 36765 rs41315493 GRCh37: 3:38592012-38592012
GRCh38: 3:38550521-38550521
18 TTN-AS1 , TTN NM_001267550.2(TTN):c.101212C>T (p.Arg33738Cys) SNV Likely benign 47633 rs56273463 GRCh37: 2:179400130-179400130
GRCh38: 2:178535403-178535403
19 TTN-AS1 , TTN NM_001267550.2(TTN):c.69130C>T (p.Pro23044Ser) SNV Likely benign 47265 rs55980498 GRCh37: 2:179441932-179441932
GRCh38: 2:178577205-178577205
20 TTN , LOC101927055 NM_001267550.2(TTN):c.4359A>T (p.Arg1453Ser) SNV Likely benign 47051 rs376857956 GRCh37: 2:179642552-179642552
GRCh38: 2:178777825-178777825
21 BAG3 NM_004281.4(BAG3):c.187C>G (p.Pro63Ala) SNV Benign 178006 rs144041999 GRCh37: 10:121429369-121429369
GRCh38: 10:119669857-119669857
22 BAG3 NM_004281.4(BAG3):c.1138C>T (p.Pro380Ser) SNV Benign 162782 rs144692954 GRCh37: 10:121436204-121436204
GRCh38: 10:119676692-119676692
23 TTN-AS1 , TTN NM_001267550.2(TTN):c.47315G>A (p.Arg15772Gln) SNV Benign 47010 rs72677233 GRCh37: 2:179482763-179482763
GRCh38: 2:178618036-178618036
24 TTN NM_001267550.2(TTN):c.18776C>G (p.Thr6259Ser) SNV Benign 46644 rs72648949 GRCh37: 2:179594107-179594107
GRCh38: 2:178729380-178729380
25 TTN NM_001267550.2(TTN):c.9359G>A (p.Arg3120Gln) SNV Benign 47636 rs72647894 GRCh37: 2:179632598-179632598
GRCh38: 2:178767871-178767871
26 HCN4 NM_005477.3(HCN4):c.2648C>G (p.Pro883Arg) SNV Benign 137542 rs148398509 GRCh37: 15:73615786-73615786
GRCh38: 15:73323445-73323445
27 TTN-AS1 , TTN NM_001267550.2(TTN):c.87877C>T (p.Arg29293Cys) SNV Benign 47470 rs191482653 GRCh37: 2:179422112-179422112
GRCh38: 2:178557385-178557385
28 TTN NM_001267550.2(TTN):c.8902+14T>A SNV Benign 137827 rs13388274 GRCh37: 2:179634392-179634392
GRCh38: 2:178769665-178769665
29 ANK2 NM_001148.6(ANK2):c.9854T>C (p.Ile3285Thr) SNV Benign 190528 rs36210417 GRCh37: 4:114279628-114279628
GRCh38: 4:113358472-113358472
30 KCNH2 NM_000238.4(KCNH2):c.2690A>C (p.Lys897Thr) SNV Benign 67427 rs1805123 GRCh37: 7:150645534-150645534
GRCh38: 7:150948446-150948446
31 AKAP9 NM_005751.4(AKAP9):c.139C>T (p.His47Tyr) SNV Benign 191549 rs35669569 GRCh37: 7:91603115-91603115
GRCh38: 7:91973801-91973801
32 KCNQ1 NM_181798.1(KCNQ1):c.40G>A (p.Val14Met) SNV not provided 67072 rs199472687 GRCh37: 11:2549192-2549192
GRCh38: 11:2527962-2527962
33 SCN5A NM_198056.2(SCN5A):c.1333C>G (p.His445Asp) SNV not provided 30046 rs199473112 GRCh37: 3:38647447-38647447
GRCh38: 3:38605956-38605956
34 SCN5A NM_198056.2(SCN5A):c.5624T>C (p.Met1875Thr) SNV not provided 68002 rs199473324 GRCh37: 3:38592239-38592239
GRCh38: 3:38550748-38550748
35 SCN5A NM_198056.2(SCN5A):c.1963G>A (p.Glu655Lys) SNV not provided 30049 rs199473579 GRCh37: 3:38640469-38640469
GRCh38: 3:38598978-38598978
36 KCNQ1 NM_181798.1(KCNQ1):c.37A>G (p.Ser13Gly) SNV not provided 3143 rs120074192 GRCh37: 11:2549189-2549189
GRCh38: 11:2527959-2527959
37 KCNQ1 NM_181798.1(KCNQ1):c.244T>C (p.Ser82Pro) SNV not provided 67094 rs199472705 GRCh37: 11:2592575-2592575
GRCh38: 11:2571345-2571345
38 KCNE2 NM_172201.1(KCNE2):c.79C>T (p.Arg27Cys) SNV not provided 6055 rs74315449 GRCh37: 21:35742856-35742856
GRCh38: 21:34370557-34370557
39 SCN5A NM_000335.4(SCN5A):c.1410C>G (p.Asn470Lys) SNV not provided 30047 rs199473115 GRCh37: 3:38646328-38646328
GRCh38: 3:38604837-38604837
40 KCNQ1 NM_181798.1(KCNQ1):c.59A>G (p.Gln20Arg) SNV not provided 67074 rs199472689 GRCh37: 11:2549211-2549211
GRCh38: 11:2527981-2527981
41 SCN5A NM_198056.2(SCN5A):c.3392C>T (p.Thr1131Ile) SNV not provided 67795 rs199473197 GRCh37: 3:38618271-38618271
GRCh38: 3:38576780-38576780
42 SCN5A NM_198056.2(SCN5A):c.5476C>T (p.Arg1826Cys) SNV not provided 67994 rs199473635 GRCh37: 3:38592387-38592387
GRCh38: 3:38550896-38550896
43 SCN5A NM_198056.2(SCN5A):c.5851G>A (p.Val1951Met) SNV not provided 68014 rs41315493 GRCh37: 3:38592012-38592012
GRCh38: 3:38550521-38550521
44 KCNE2 NM_172201.1(KCNE2):c.269A>G (p.Glu90Gly) SNV not provided 67617 rs199473366 GRCh37: 21:35743046-35743046
GRCh38: 21:34370747-34370747

Expression for Atrial Fibrillation

Search GEO for disease gene expression data for Atrial Fibrillation.

Pathways for Atrial Fibrillation

Pathways related to Atrial Fibrillation according to KEGG:

36
# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270
2 Adrenergic signaling in cardiomyocytes hsa04261

Pathways related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 SCN5A SCN4B SCN3B SCN2B SCN1B GJA5
2
Show member pathways
12.84